HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use JARDIANCE safely and effectively. See full prescribing information for JARDIANCE.

JARDIANCE® (empagliflozin) tablets, for oral use
Initial U.S. Approval: 2014

• Limitation of Use: indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1.1)

• Initial U.S. Approval: 2014

JARDIANCE safely and effectively. See full prescribing information for these highlights do not include all the information needed to use JARDIANCE.

HIGHLIGHTS OF PRESCRIBING INFORMATION
WARNINGS AND PRECAUTIONS
-----------------------
• The recommended dose of JARDIANCE is 10 mg once daily, taken in the morning, with or without food (2.1)
• Dose may be increased to 25 mg once daily (2.1)
• Assess renal function before initiating JARDIANCE. Do not initiate JARDIANCE if eGFR is below 45 mL/min/1.73 m² (2.2)
• Discontinue JARDIANCE if eGFR falls persistently below 45 mL/min/1.73 m² (2.2)

DOSAGE FORMS AND STRENGTHS
Tablets: 10 mg, 25 mg (3)

CONTRAINDICATIONS
• History of serious hypersensitivity reaction to JARDIANCE (4)
• Severe renal impairment, end-stage renal disease, or dialysis (4)

WARNINGS AND PRECAUTIONS
• Hypotension Before initiating JARDIANCE assess and correct volume status in patients with renal impairment, the elderly, in patients with low systolic blood pressure, and in patients on diuretics. Monitor for signs and symptoms during therapy. (5.1)
• Impairment in renal function Monitor renal function during therapy. More frequent monitoring is recommended in patients with eGFR below 60 mL/min/1.73 m² (5.2)
• Hypoglycemia Consider lowering the dose of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating JARDIANCE (5.3)
• Genital mycotic infections Monitor and treat as appropriate (5.4)
• Urinary tract infections Monitor and treat as appropriate (5.5)
• Increased LDL-C Monitor and treat as appropriate (5.6)
• Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JARDIANCE (5.7)

ADVERSE REACTIONS
• The most common adverse reactions associated with JARDIANCE (5% or greater incidence) were urinary tract infections and female genital mycotic infections (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257 or 1-800-459-9906 TTY, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS
• Pregnancy No adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefits justifies the potential risk to the fetus. (8.1)
• Nursing mothers Discontinue JARDIANCE or discontinue nursing (8.3)
• Geriatric patients Higher incidence of adverse reactions related to volume depletion and reduced renal function (5.1, 5.2, 8.5)
• Patients with renal impairment Higher incidence of adverse reactions related to reduced renal function (2.2, 5.2, 8.6)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 8/2014

FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
1.1 Limitation of Use
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosage
2.2 Patients with Renal Impairment
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Hypotension
5.2 Impairment in Renal Function
5.3 Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues
5.4 Genital Mycotic Infections
5.5 Urinary Tract Infections
5.6 Increased Low-Density Lipoprotein Cholesterol (LDL-C)
5.7 Macrovascular Outcomes
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
7 DRUG INTERACTIONS
7.1 Diuretics
7.2 Insulin or Insulin Secretagogues
7.3 Positive Urine Glucose Test
7.4 Interference with 1,5-anhydroglucitol (1,5-AG) Assay
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.3 Nursing Mothers
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Renal Impairment
8.7 Hepatic Impairment
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14 CLINICAL STUDIES
14.1 Monotherapy
14.2 Combination Therapy
14.3 Renal Impairment
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.
FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE
JARDIANCE is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14)].

1.1 Limitation of Use
JARDIANCE is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosage
The recommended dose of JARDIANCE is 10 mg once daily in the morning, taken with or without food. In patients tolerating JARDIANCE, the dose may be increased to 25 mg [see Clinical Studies (14)].

In patients with volume depletion, correcting this condition prior to initiation of JARDIANCE is recommended [see Warnings and Precautions (5.1), Use in Specific Populations (8.5), and Patient Counseling Information (17)].

2.2 Patients with Renal Impairment
Assessment of renal function is recommended prior to initiation of JARDIANCE and periodically thereafter.

JARDIANCE should not be initiated in patients with an eGFR less than 45 mL/min/1.73 m².

No dose adjustment is needed in patients with an eGFR greater than or equal to 45 mL/min/1.73 m².

JARDIANCE should be discontinued if eGFR is persistently less than 45 mL/min/1.73 m² [see Warning and Precautions (5.1, 5.2), and Use in Specific Populations (8.6)].

3 DOSAGE FORMS AND STRENGTHS
• JARDIANCE (empagliflozin) 10 mg tablets are pale yellow, round, biconvex and bevel-edged, film-coated tablets debossed with “S 10” on one side and the Boehringer Ingelheim company symbol on the other side.
• JARDIANCE (empagliflozin) 25 mg tablets are pale yellow, oval, biconvex, film-coated tablets debossed with “S 25” on one side and the Boehringer Ingelheim company symbol on the other side.

4 CONTRAINDICATIONS
• History of serious hypersensitivity reaction to JARDIANCE.
• Severe renal impairment, end-stage renal disease, or dialysis [see Use in Specific Populations (8.6)].

5 WARNINGS AND PRECAUTIONS
5.1 Hypotension
JARDIANCE causes intravascular volume contraction. Symptomatic hypotension may occur after initiating JARDIANCE [see Adverse Reactions (6.1)] particularly in patients with renal impairment, the elderly, in patients with low systolic blood pressure, and in patients on diuretics. Before initiating JARDIANCE, assess for volume contraction and correct volume status if indicated. Monitor for signs and symptoms of hypotension after initiating therapy and increase monitoring in clinical situations where volume contraction is expected [see Use in Specific Populations (8.5)].
5.2 Impairment in Renal Function
JARDIANCE increases serum creatinine and decreases eGFR [see Adverse Reactions (6.1)]. The risk of impaired renal function with JARDIANCE is increased in elderly patients and patients with moderate renal impairment. More frequent monitoring of renal function is recommended in these patients [see Use in Specific Populations (8.5, 8.6)]. Renal function should be evaluated prior to initiating JARDIANCE and periodically thereafter.

5.3 Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues
Insulin and insulin secretagogues are known to cause hypoglycemia. The risk of hypoglycemia is increased when JARDIANCE is used in combination with insulin secretagogues (e.g., sulfonylurea) or insulin [see Adverse Reactions (6.1)]. Therefore, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia when used in combination with JARDIANCE.

5.4 Genital Mycotic Infections
JARDIANCE increases the risk for genital mycotic infections [see Adverse Reactions (6.1)]. Patients with a history of chronic or recurrent genital mycotic infections were more likely to develop mycotic genital infections. Monitor and treat as appropriate.

5.5 Urinary Tract Infections
JARDIANCE increases the risk for urinary tract infections [see Adverse Reactions (6.1)]. Monitor and treat as appropriate.

5.6 Increased Low-Density Lipoprotein Cholesterol (LDL-C)
Increases in LDL-C can occur with JARDIANCE [see Adverse Reactions (6.1)]. Monitor and treat as appropriate.

5.7 Macrovascular Outcomes
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JARDIANCE or any other antidiabetic drug.

6 ADVERSE REACTIONS
The following important adverse reactions are described below and elsewhere in the labeling:

- Hypotension [see Warnings and Precautions (5.1)]
- Impairment in Renal Function [see Warnings and Precautions (5.2)]
- Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues [see Warnings and Precautions (5.3)]
- Genital Mycotic Infections [see Warnings and Precautions (5.4)]
- Urinary Tract Infections [see Warnings and Precautions (5.5)]
- Increased Low-Density Lipoprotein Cholesterol (LDL-C) [see Warnings and Precautions (5.6)]

6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Pool of Placebo-Controlled Trials evaluating JARDIANCE 10 and 25 mg
The data in Table 1 are derived from a pool of four 24-week placebo-controlled trials and 18-week data from a placebo-controlled trial with insulin. JARDIANCE was used as monotherapy in one trial and as add-on therapy in four trials [see Clinical Studies (14)].

These data reflect exposure of 1976 patients to JARDIANCE with a mean exposure duration of approximately 23 weeks. Patients received placebo (N=995), JARDIANCE 10 mg (N=999), or JARDIANCE 25 mg (N=977) once daily. The mean age of the population was 56 years and 3% were older than 75 years of age. More than half (55%) of the population was male; 46% were White, 50% were Asian, and 3% were Black or African American. At baseline, 57% of the population had diabetes more than 5 years and had a mean hemoglobin A1c (HbA1c) of 8%. Established microvascular complications of diabetes at baseline included diabetic nephropathy (7%), retinopathy (8%), or neuropathy (16%). Baseline renal function was normal or mildly impaired in 91% of patients and moderately impaired in 9% of patients (mean eGFR 86.8 mL/min/1.73 m²).

Table 1 shows common adverse reactions (excluding hypoglycemia) associated with the use of JARDIANCE. The adverse reactions were not present at baseline, occurred more commonly on JARDIANCE than on placebo and occurred in greater than or equal to 2% of patients treated with JARDIANCE 10 mg or JARDIANCE 25 mg.

**Table 1**  Adverse Reactions Reported in ≥2% of Patients Treated with JARDIANCE and Greater than Placebo in Pooled Placebo-Controlled Clinical Studies of JARDIANCE Monotherapy or Combination Therapy

<table>
<thead>
<tr>
<th></th>
<th>Placebo N=995</th>
<th>JARDIANCE 10 mg N=999</th>
<th>JARDIANCE 25 mg N=977</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urinary tract infection^a</td>
<td>7.6%</td>
<td>9.3%</td>
<td>7.6%</td>
</tr>
<tr>
<td>Female genital mycotic infections^b</td>
<td>1.5%</td>
<td>5.4%</td>
<td>6.4%</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>3.8%</td>
<td>3.1%</td>
<td>4.0%</td>
</tr>
<tr>
<td>Increased urination^c</td>
<td>1.0%</td>
<td>3.4%</td>
<td>3.2%</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>3.4%</td>
<td>3.9%</td>
<td>2.9%</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>2.2%</td>
<td>2.4%</td>
<td>2.3%</td>
</tr>
<tr>
<td>Male genital mycotic infections^d</td>
<td>0.4%</td>
<td>3.1%</td>
<td>1.6%</td>
</tr>
<tr>
<td>Nausea</td>
<td>1.4%</td>
<td>2.3%</td>
<td>1.1%</td>
</tr>
</tbody>
</table>

^aPredefined adverse event grouping, including, but not limited to, urinary tract infection, asymptomatic bacteriuria, cystitis
^bFemale genital mycotic infections include the following adverse reactions: vulvovaginal mycotic infection, vaginal infection, vulvitis, vulvovaginal candidiasis, genital infection, genital candidiasis, genital infection fungal, genitourinary tract infection, vulvovaginitis, cervicitis, urogenital infection fungal, vaginitis bacterial. Percentages calculated with the number of female subjects in each group as denominator: placebo (N=481), JARDIANCE 10 mg (N=443), JARDIANCE 25 mg (N=420).
^cPredefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia
^dMale genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection. Percentages calculated with the number of male subjects in each group as denominator: placebo (N=514), JARDIANCE 10 mg (N=556), JARDIANCE 25 mg (N=557).

Thirst (including polydipsia) was reported in 0%, 1.7%, and 1.5% for placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg, respectively.

**Volume Depletion**
JARDIANCE causes an osmotic diuresis, which may lead to intravascular volume contraction and adverse reactions related to volume depletion. In the pool of five placebo-controlled clinical trials, adverse reactions related to volume depletion (e.g., blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported by 0.3%, 0.5%, and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg respectively.
JARDIANCE may increase the risk of hypotension in patients at risk for volume contraction [see Warnings and Precautions (5.1) and Use in Specific Populations (8.5, 8.6)].

Increased Urination
In the pool five placebo-controlled clinical trials, adverse reactions of increased urination (e.g., polyuria, pollakiuria, and nocturia) occurred more frequently on JARDIANCE than on placebo (see Table 1). Specifically, nocturia was reported by 0.4%, 0.3%, and 0.8% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg, respectively.

Impairment in Renal Function
Use of JARDIANCE was associated with increases in serum creatinine and decreases in eGFR (see Table 2). Patients with moderate renal impairment at baseline had larger mean changes. [see Warnings and Precautions (5.2) and Use in Specific Populations (8.5, 8.6)].

Table 2  Changes from Baseline in Serum Creatinine and eGFR in the Pool of Four 24-week Placebo-Controlled Studies and Renal Impairment Study

<table>
<thead>
<tr>
<th></th>
<th>Pool of 24-Week Placebo-Controlled Studies</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>JARDIANCE 10 mg</td>
<td>JARDIANCE 25 mg</td>
<td></td>
</tr>
<tr>
<td>Baseline Mean</td>
<td>N</td>
<td>825</td>
<td>830</td>
<td>822</td>
</tr>
<tr>
<td></td>
<td>Creatinine (mg/dL)</td>
<td>0.84</td>
<td>0.85</td>
<td>0.85</td>
</tr>
<tr>
<td></td>
<td>eGFR (mL/min/1.73 m²)</td>
<td>87.3</td>
<td>87.1</td>
<td>87.8</td>
</tr>
<tr>
<td>Week 12 Change</td>
<td>N</td>
<td>771</td>
<td>797</td>
<td>783</td>
</tr>
<tr>
<td></td>
<td>Creatinine (mg/dL)</td>
<td>0.00</td>
<td>0.02</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>eGFR (mL/min/1.73 m²)</td>
<td>-0.3</td>
<td>-1.3</td>
<td>-1.4</td>
</tr>
<tr>
<td>Week 24 Change</td>
<td>N</td>
<td>708</td>
<td>769</td>
<td>754</td>
</tr>
<tr>
<td></td>
<td>Creatinine (mg/dL)</td>
<td>0.00</td>
<td>0.01</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>eGFR (mL/min/1.73 m²)</td>
<td>-0.3</td>
<td>-0.6</td>
<td>-1.4</td>
</tr>
</tbody>
</table>

|                          | Moderate Renal Impairment<sup>a</sup>     |                          |                          |                          |
|                          | Placebo                                  | JARDIANCE 25 mg          |                          |                          |
| Baseline                 | N                                         | 187                      | --                       | 187                      |
|                          | Creatinine (mg/dL)                        | 1.49                     | --                       | 1.46                     |
|                          | eGFR (mL/min/1.73 m²)                     | 44.3                     | --                       | 45.4                     |
| Week 12 Change           | N                                         | 176                      | --                       | 179                      |
|                          | Creatinine (mg/dL)                        | 0.01                     | --                       | 0.12                     |
|                          | eGFR (mL/min/1.73 m²)                     | 0.1                      | --                       | -3.8                     |
| Week 24 Change           | N                                         | 170                      | --                       | 171                      |
|                          | Creatinine (mg/dL)                        | 0.01                     | --                       | 0.10                     |
|                          | eGFR (mL/min/1.73 m²)                     | 0.2                      | --                       | -3.2                     |
| Week 52 Change           | N                                         | 164                      | --                       | 162                      |
|                          | Creatinine (mg/dL)                        | 0.02                     | --                       | 0.11                     |
|                          | eGFR (mL/min/1.73 m²)                     | -0.3                     | --                       | -2.8                     |

<sup>a</sup>Subset of patients from renal impairment study with eGFR 30 to less than 60 mL/min/1.73 m²
Hypoglycemia
The incidence of hypoglycemia by study is shown in Table 3. The incidence of hypoglycemia increased when JARDIANCE was administered with insulin or sulfonylurea [see Warnings and Precautions (5.3)].

Table 3 Incidence of Overalla and Severeb Hypoglycemic Events in Controlled Clinical Studies

<table>
<thead>
<tr>
<th>Monotherapy (24 weeks)</th>
<th>Placebo (n=229)</th>
<th>JARDIANCE 10 mg (n=224)</th>
<th>JARDIANCE 25 mg (n=223)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall (%)</td>
<td>0.4%</td>
<td>0.4%</td>
<td>0.4%</td>
</tr>
<tr>
<td>Severe (%)</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>In Combination with Metformin (24 weeks)</td>
<td>Placebo + Metformin (n=206)</td>
<td>JARDIANCE 10 mg + Metformin (n=217)</td>
<td>JARDIANCE 25 mg + Metformin (n=214)</td>
</tr>
<tr>
<td>Overall (%)</td>
<td>0.5%</td>
<td>1.8%</td>
<td>1.4%</td>
</tr>
<tr>
<td>Severe (%)</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>In Combination with Metformin + Sulfonylurea (24 weeks)</td>
<td>Placebo (n=225)</td>
<td>JARDIANCE 10 mg + Metformin + Sulfonylurea (n=224)</td>
<td>JARDIANCE 25 mg + Metformin + Sulfonylurea (n=217)</td>
</tr>
<tr>
<td>Overall (%)</td>
<td>8.4%</td>
<td>16.1%</td>
<td>11.5%</td>
</tr>
<tr>
<td>Severe (%)</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>In Combination with Pioglitazone +/- Metformin (24 weeks)</td>
<td>Placebo (n=165)</td>
<td>JARDIANCE 10 mg + Pioglitazone +/- Metformin (n=165)</td>
<td>JARDIANCE 25 mg + Pioglitazone +/- Metformin (n=168)</td>
</tr>
<tr>
<td>Overall (%)</td>
<td>1.8%</td>
<td>1.2%</td>
<td>2.4%</td>
</tr>
<tr>
<td>Severe (%)</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>In Combination with Insulin (18 weeks)</td>
<td>Placebo (n=170)</td>
<td>JARDIANCE 10 mg (n=169)</td>
<td>JARDIANCE 25 mg (n=155)</td>
</tr>
<tr>
<td>Overall (%)</td>
<td>20.6%</td>
<td>19.5%</td>
<td>28.4%</td>
</tr>
<tr>
<td>Severe (%)</td>
<td>0%</td>
<td>0%</td>
<td>1.3%</td>
</tr>
</tbody>
</table>

aOverall hypoglycemic events: plasma or capillary glucose of less than or equal to 70 mg/dL
bSevere hypoglycemic events: requiring assistance regardless of blood glucose
CInsulin dose could not be adjusted during the initial 18 week treatment period

Genital Mycotic Infections
In the pool five placebo-controlled clinical trials, the incidence of genital mycotic infections (e.g., vaginal mycotic infection, vaginal infection, genital infection fungal, vulvovaginal candidiasis, and vulvitis) was increased in patients treated with JARDIANCE compared to placebo, occurring in 0.9%, 4.1%, and 3.7% of patients randomized to placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg, respectively. Discontinuation from study due to genital infection occurred in 0% of placebo-treated patients and 0.2% of patients treated with either JARDIANCE 10 or 25 mg.

Genital mycotic infections occurred more frequently in female than male patients (see Table 1).

Phimosis occurred more frequently in male patients treated with JARDIANCE 10 mg (less than 0.1%) and JARDIANCE 25 mg (0.1%) than placebo (0%).

Urinary Tract Infections
In the pool five placebo-controlled clinical trials, the incidence of urinary tract infections (e.g., urinary tract infection, asymptomatic bacteriuria, and cystitis) was increased in patients treated with JARDIANCE compared to placebo (see Table 1). Patients with a history of chronic or recurrent urinary tract infections were more likely to experience a urinary tract infection. The rate of treatment discontinuation due to urinary tract infections was 0.1%, 0.2%, and 0.1% for placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg, respectively.
Urinary tract infections occurred more frequently in female patients. The incidence of urinary tract infections in female patients randomized to placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg was 16.6%, 18.4%, and 17.0%, respectively. The incidence of urinary tract infections in male patients randomized to placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg was 3.2%, 3.6%, and 4.1%, respectively [see Warnings and Precautions (5.5) and Use in Specific Populations (8.5)].

**Laboratory Tests**

**Increase in Low-Density Lipoprotein Cholesterol (LDL-C)**
Dose-related increases in low-density lipoprotein cholesterol (LDL-C) were observed in patients treated with JARDIANCE. LDL-C increased by 2.3%, 4.6%, and 6.5% in patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg, respectively [see Warnings and Precautions (5.6)]. The range of mean baseline LDL-C levels was 90.3 to 90.6 mg/dL across treatment groups.

**Increase in Hematocrit**
In a pool of four placebo-controlled studies, median hematocrit decreased by 1.3% in placebo and increased by 2.8% in JARDIANCE 10 mg and 2.8% in JARDIANCE 25 mg treated patients. At the end of treatment, 0.6%, 2.7%, and 3.5% of patients with hematocrits initially within the reference range had values above the upper limit of the reference range with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg, respectively.

7 **DRUG INTERACTIONS**

7.1 **Diuretics**
Coadministration of empagliflozin with diuretics resulted in increased urine volume and frequency of voids, which might enhance the potential for volume depletion [see Warnings and Precautions (5.1)].

7.2 **Insulin or Insulin Secretagogues**
Coadministration of empagliflozin with insulin or insulin secretagogues increases the risk for hypoglycemia [see Warnings and Precautions (5.3)]

7.3 **Positive Urine Glucose Test**
Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Use alternative methods to monitor glycemic control.

7.4 **Interference with 1,5-anhydroglucitol (1,5-AG) Assay**
Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.

8 **USE IN SPECIFIC POPULATIONS**

8.1 **Pregnancy**

*Pregnancy Category C*

There are no adequate and well-controlled studies of JARDIANCE in pregnant women. JARDIANCE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Based on results from animal studies, empagliflozin may affect renal development and maturation. In studies conducted in rats, empagliflozin crosses the placenta and reaches fetal tissues. During pregnancy, consider appropriate alternative therapies, especially during the second and third trimesters.
Empagliflozin was not teratogenic in embryo-fetal development studies in rats and rabbits up to 300 mg/kg/day, which approximates 48-times and 128-times, respectively, the maximum clinical dose of 25 mg. At higher doses, causing maternal toxicity, malformations of limb bones increased in fetuses at 700 mg/kg/day or 154 times the 25 mg maximum clinical dose in rats. In the rabbit, higher doses of empagliflozin resulted in maternal and fetal toxicity at 700 mg/kg/day, or 139 times the 25 mg maximum clinical dose.

In pre- and postnatal development studies in pregnant rats, empagliflozin was administered from gestation day 6 through to lactation day 20 (weaning) at up to 100 mg/kg/day (approximately 16 times the 25 mg maximum clinical dose) without maternal toxicity. Reduced body weight was observed in the offspring at greater than or equal to 30 mg/kg/day (approximately 4 times the 25 mg maximum clinical dose).

8.3 Nursing Mothers
It is not known if JARDIANCE is excreted in human milk. Empagliflozin is secreted in the milk of lactating rats reaching levels up to 5 times higher than that in maternal plasma. Since human kidney maturation occurs in utero and during the first 2 years of life when lactational exposure may occur, there may be risk to the developing human kidney. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from JARDIANCE, a decision should be made whether to discontinue nursing or to discontinue JARDIANCE, taking into account the importance of the drug to the mother.

8.4 Pediatric Use
The safety and effectiveness of JARDIANCE in pediatric patients under 18 years of age have not been established.

8.5 Geriatric Use
No JARDIANCE dosage change is recommended based on age [see Dosage and Administration (2)]. A total of 2721 (32%) patients treated with empagliflozin were 65 years of age and older, and 491 (6%) were 75 years of age and older. JARDIANCE is expected to have diminished efficacy in elderly patients with renal impairment [see Use in Specific Populations (8.6)]. The risk of volume depletion-related adverse reactions increased in patients who were 75 years of age and older to 2.1%, 2.3%, and 4.4% for placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg. The risk of urinary tract infections increased in patients who were 75 years of age and older to 10.5%, 15.7%, and 15.1% in patients randomized to placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg, respectively [see Warning and Precautions (5.1) and Adverse Reactions (6.1)].

8.6 Renal Impairment
The efficacy and safety of JARDIANCE were evaluated in a study of patients with mild and moderate renal impairment [see Clinical Studies (14.3)]. In this study, 195 patients exposed to JARDIANCE had an eGFR between 60 and 90 mL/min/1.73 m², 91 patients exposed to JARDIANCE had an eGFR between 45 and 60 mL/min/1.73 m² and 97 patients exposed to JARDIANCE had an eGFR between 30 and 45 mL/min/1.73 m². The glucose lowering benefit of JARDIANCE 25 mg decreased in patients with worsening renal function. The risks of renal impairment [see Warnings and Precautions (5.2)], volume depletion adverse reactions and urinary tract infection-related adverse reactions increased with worsening renal function.

The efficacy and safety of JARDIANCE have not been established in patients with severe renal impairment, with ESRD, or receiving dialysis. JARDIANCE is not expected to be effective in these patient populations [see Dosage and Administration (2.2), Contraindications (4) and Warnings and Precautions (5.1, 5.2)].

8.7 Hepatic Impairment
JARDIANCE may be used in patients with hepatic impairment [see Clinical Pharmacology (12.3)].
10 OVERDOSAGE
In the event of an overdose with JARDIANCE, contact the Poison Control Center. Employ the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment) as dictated by the patient’s clinical status. Removal of empagliflozin by hemodialysis has not been studied.

11 DESCRIPTION
JARDIANCE tablets contain empagliflozin, an orally-active inhibitor of the sodium-glucose co-transporter 2 (SGLT2).

The chemical name of empagliflozin is D-Glucitol,1,5-anhydro-1-C-[4-chloro-3-[[4-[[3S]-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, (1S).

Its molecular formula is C_{23}H_{27}ClO_{7} and the molecular weight is 450.91. The structural formula is:

![Structural formula of empagliflozin](image)

Empagliflozin is a white to yellowish, non-hygroscopic powder. It is very slightly soluble in water, sparingly soluble in methanol, slightly soluble in ethanol and acetonitrile; soluble in 50% acetonitrile/water; and practically insoluble in toluene.

Each film-coated tablet of JARDIANCE contains 10 mg or 25 mg of empagliflozin (free base) and the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate. In addition, the film coating contains the following inactive ingredients: hypromellose, titanium dioxide, talc, polyethylene glycol, and yellow ferric oxide.

12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Sodium-glucose co-transporter 2 (SGLT2) is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.

12.2 Pharmacodynamics

*Urinary Glucose Excretion*
In patients with type 2 diabetes, urinary glucose excretion increased immediately following a dose of JARDIANCE and was maintained at the end of a 4-week treatment period averaging at approximately 64 grams per day with 10 mg empagliflozin and 78 grams per day with 25 mg JARDIANCE once daily [see Clinical Studies (14)].

*Urinary Volume*
In a 5-day study, mean 24-hour urine volume increase from baseline was 341 mL on Day 1 and 135 mL on Day 5 of empagliflozin 25 mg once daily treatment.
Cardiac Electrophysiology
In a randomized, placebo-controlled, active-comparator, crossover study, 30 healthy subjects were administered a single oral dose of JARDIANCE 25 mg, JARDIANCE 200 mg (8 times the maximum dose), moxifloxacin, and placebo. No increase in QTc was observed with either 25 mg or 200 mg empagliflozin.

12.3 Pharmacokinetics

Absorption
The pharmacokinetics of empagliflozin has been characterized in healthy volunteers and patients with type 2 diabetes and no clinically relevant differences were noted between the two populations. After oral administration, peak plasma concentrations of empagliflozin were reached at 1.5 hours post-dose. Thereafter, plasma concentrations declined in a biphasic manner with a rapid distribution phase and a relatively slow terminal phase. The steady state mean plasma AUC and C\text{max} were 1870 nmol·h/L and 259 nmol/L, respectively, with 10 mg empagliflozin once daily treatment, and 4740 nmol·h/L and 687 nmol/L, respectively, with 25 mg empagliflozin once daily treatment. Systemic exposure of empagliflozin increased in a dose-proportional manner in the therapeutic dose range. The single-dose and steady-state pharmacokinetic parameters of empagliflozin were similar, suggesting linear pharmacokinetics with respect to time.

Administration of 25 mg empagliflozin after intake of a high-fat and high-calorie meal resulted in slightly lower exposure; AUC decreased by approximately 16% and C\text{max} decreased by approximately 37%, compared to fasted condition. The observed effect of food on empagliflozin pharmacokinetics was not considered clinically relevant and empagliflozin may be administered with or without food.

Distribution
The apparent steady-state volume of distribution was estimated to be 73.8 L based on a population pharmacokinetic analysis. Following administration of an oral \([^{14}C]\)-empagliflozin solution to healthy subjects, the red blood cell partitioning was approximately 36.8% and plasma protein binding was 86.2%.

Metabolism
No major metabolites of empagliflozin were detected in human plasma and the most abundant metabolites were three glucuronide conjugates (2-O-, 3-O-, and 6-O-glucuronide). Systemic exposure of each metabolite was less than 10% of total drug-related material. \textit{In vitro} studies suggested that the primary route of metabolism of empagliflozin in humans is glucuronidation by the uridine 5’-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8, and UGT1A9.

Elimination
The apparent terminal elimination half-life of empagliflozin was estimated to be 12.4 h and apparent oral clearance was 10.6 L/h based on the population pharmacokinetic analysis. Following once-daily dosing, up to 22% accumulation, with respect to plasma AUC, was observed at steady-state, which was consistent with empagliflozin half-life. Following administration of an oral \([^{14}C]\)-empagliflozin solution to healthy subjects, approximately 95.6% of the drug-related radioactivity was eliminated in feces (41.2%) or urine (54.4%). The majority of drug-related radioactivity recovered in feces was unchanged parent drug and approximately half of drug-related radioactivity excreted in urine was unchanged parent drug.

Specific Populations
Renal Impairment
In patients with mild (eGFR: 60 to less than 90 mL/min/1.73 m²), moderate (eGFR: 30 to less than 60 mL/min/1.73 m²), and severe (eGFR: less than 30 mL/min/1.73 m²) renal impairment and subjects with kidney failure/end stage renal disease (ESRD) patients, AUC of empagliflozin increased by approximately 18%, 20%, 66%, and 48%, respectively, compared to subjects with normal renal function. Peak plasma levels of empagliflozin were similar in subjects with moderate renal impairment and kidney failure/ESRD compared to
patients with normal renal function. Peak plasma levels of empagliflozin were roughly 20% higher in subjects with mild and severe renal impairment as compared to subjects with normal renal function. Population pharmacokinetic analysis showed that the apparent oral clearance of empagliflozin decreased, with a decrease in eGFR leading to an increase in drug exposure. However, the fraction of empagliflozin that was excreted unchanged in urine, and urinary glucose excretion, declined with decrease in eGFR.

**Hepatic Impairment**
In subjects with mild, moderate, and severe hepatic impairment according to the Child-Pugh classification, AUC of empagliflozin increased by approximately 23%, 47%, and 75%, and C\(_{\text{max}}\) increased by approximately 4%, 23%, and 48%, respectively, compared to subjects with normal hepatic function.

**Effects of Age, Body Mass Index, Gender, and Race**
Based on the population PK analysis, age, body mass index (BMI), gender and race (Asians versus primarily Whites) do not have a clinically meaningful effect on pharmacokinetics of empagliflozin [see Use in Specific Populations (8.5)].

**Pediatric**
Studies characterizing the pharmacokinetics of empagliflozin in pediatric patients have not been performed.

**Drug Interactions**

*In vitro* Assessment of Drug Interactions
*In vitro* data suggest that the primary route of metabolism of empagliflozin in humans is glucuronidation by the uridine 5'-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8, and UGT1A9. Empagliflozin does not inhibit, inactivate, or induce CYP450 isoforms. Empagliflozin also does not inhibit UGT1A1. Therefore, no effect of empagliflozin is anticipated on concomitantly administered drugs that are substrates of the major CYP450 isoforms or UGT1A1. The effect of UGT induction (e.g., induction by rifampicin or any other UGT enzyme inducer) on empagliflozin exposure has not been evaluated.

Empagliflozin is a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), but it does not inhibit these efflux transporters at therapeutic doses. Based on *in vitro* studies, empagliflozin is considered unlikely to cause interactions with drugs that are P-gp substrates. Empagliflozin is a substrate of the human uptake transporters OAT3, OATP1B1, and OATP1B3, but not OAT1 and OCT2. Empagliflozin does not inhibit any of these human uptake transporters at clinically relevant plasma concentrations and, therefore, no effect of empagliflozin is anticipated on concomitantly administered drugs that are substrates of these uptake transporters.

*In vivo* Assessment of Drug Interactions
No dose adjustment of JARDIANCE is recommended when coadministered with commonly prescribed medicinal products based on results of the described pharmacokinetic studies. Empagliflozin pharmacokinetics were similar with and without coadministration of metformin, glimepiride, pioglitazone, sitagliptin, linaclotide, warfarin, verapamil, ramipril, simvastatin, hydrochlorothiazide, and torasemide in healthy volunteers (see Figure 1). The observed increases in overall exposure (AUC) of empagliflozin following coadministration with gemfibrozil, rifampicin, or probenecid are not clinically relevant. In subjects with normal renal function, coadministration of empagliflozin with probenecid resulted in a 30% decrease in the fraction of empagliflozin excreted in urine without any effect on 24-hour urinary glucose excretion. The relevance of this observation to patients with renal impairment is unknown.
Figure 1  Effect of Various Medications on the Pharmacokinetics of Empagliflozin as Displayed as 90% Confidence Interval of Geometric Mean AUC and $C_{\text{max}}$ Ratios [reference lines indicate 100% (80% - 125%)]

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dose/Course</th>
<th>AUC/Cmax</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metformin</td>
<td>1000 mg, twice daily&lt;sup&gt;a&lt;/sup&gt;</td>
<td>AUC/Cmax</td>
</tr>
<tr>
<td>Glimepiride</td>
<td>1 mg, single dose&lt;sup&gt;a&lt;/sup&gt;</td>
<td>AUC/Cmax</td>
</tr>
<tr>
<td>Pioglitazone</td>
<td>45 mg, once daily&lt;sup&gt;a&lt;/sup&gt;</td>
<td>AUC/Cmax</td>
</tr>
<tr>
<td>Sitagliptin</td>
<td>100 mg, once daily&lt;sup&gt;b&lt;/sup&gt;</td>
<td>AUC/Cmax</td>
</tr>
<tr>
<td>Linagliptin</td>
<td>5 mg, once daily&lt;sup&gt;a&lt;/sup&gt;</td>
<td>AUC/Cmax</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>40 mg, single dose&lt;sup&gt;b&lt;/sup&gt;</td>
<td>AUC/Cmax</td>
</tr>
<tr>
<td>Warfarin</td>
<td>25 mg, single dose&lt;sup&gt;c&lt;/sup&gt;</td>
<td>AUC/Cmax</td>
</tr>
<tr>
<td>Verapamil</td>
<td>120 mg, single dose&lt;sup&gt;b&lt;/sup&gt;</td>
<td>AUC/Cmax</td>
</tr>
<tr>
<td>Ramipril</td>
<td>5 mg, once daily&lt;sup&gt;d&lt;/sup&gt;</td>
<td>AUC/Cmax</td>
</tr>
<tr>
<td>Gemfibrozil</td>
<td>600 mg, twice daily&lt;sup&gt;b&lt;/sup&gt;</td>
<td>AUC/Cmax</td>
</tr>
<tr>
<td>Hydrochlorothiazide, 25 mg, once daily&lt;sup&gt;c&lt;/sup&gt;</td>
<td>AUC/Cmax</td>
<td></td>
</tr>
<tr>
<td>Torasemide</td>
<td>5 mg, once daily&lt;sup&gt;f&lt;/sup&gt;</td>
<td>AUC/Cmax</td>
</tr>
<tr>
<td>Rifampin</td>
<td>600 mg, single dose&lt;sup&gt;d&lt;/sup&gt;</td>
<td>AUC/Cmax</td>
</tr>
<tr>
<td>Probenecid</td>
<td>500 mg, twice daily&lt;sup&gt;d&lt;/sup&gt;</td>
<td>AUC/Cmax</td>
</tr>
</tbody>
</table>

<sup>a</sup>empagliflozin, 50 mg, once daily; <sup>b</sup>empagliflozin, 25 mg, single dose; <sup>c</sup>empagliflozin, 25 mg, once daily; <sup>d</sup>empagliflozin, 10 mg, single dose
Empagliflozin had no clinically relevant effect on the pharmacokinetics of metformin, glimepiride, pioglitazone, sitagliptin, linagliptin, warfarin, digoxin, ramipril, simvastatin, hydrochlorothiazide, torasemide, and oral contraceptives when coadministered in healthy volunteers (see Figure 2).

Figure 2  Effect of Empagliflozin on the Pharmacokinetics of Various Medications as Displayed as 90% Confidence Interval of Geometric Mean AUC and $C_{\text{max}}$ Ratios [reference lines indicate 100% (80% - 125%)]

13  NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis
Carcinogenesis was evaluated in 2-year studies conducted in CD-1 mice and Wistar rats. Empagliflozin did not increase the incidence of tumors in female rats dosed at 100, 300, or 700 mg/kg/day (up to 72 times the exposure from the maximum clinical dose of 25 mg). In male rats, hemangiomas of the mesenteric lymph node were increased significantly at 700 mg/kg/day or approximately 42 times the exposure from a 25 mg clinical dose. Empagliflozin did not increase the incidence of tumors in female mice dosed at 100, 300, or 1000 mg/kg/day (up to 62 times the exposure from a 25 mg clinical dose). Renal tubule adenomas and carcinomas were observed in male mice at 1000 mg/kg/day, which is approximately 45 times the exposure of the maximum clinical dose of 25 mg.

Reference ID: 3603272
Mutagenesis
Empagliflozin was not mutagenic or clastogenic with or without metabolic activation in the in vitro Ames bacterial mutagenicity assay, the in vitro L5178Y tk^+/− mouse lymphoma cell assay, and an in vivo micronucleus assay in rats.

Impairment of Fertility
Empagliflozin had no effects on mating, fertility or early embryonic development in treated male or female rats up to the high dose of 700 mg/kg/day (approximately 155 times the 25 mg clinical dose in males and females, respectively).

14 CLINICAL STUDIES
JARDIANCE has been studied as monotherapy and in combination with metformin, sulfonylurea, pioglitazone, and insulin. JARDIANCE has also been studied in patients with type 2 diabetes with mild or moderate renal impairment.

In patients with type 2 diabetes, treatment with JARDIANCE reduced hemoglobin A1c (HbA1c), compared to placebo. The reduction in HbA1c for JARDIANCE compared with placebo was observed across subgroups including gender, race, geographic region, baseline BMI and duration of disease.

14.1 Monotherapy
A total of 986 patients with type 2 diabetes participated in a double-blind, placebo-controlled study to evaluate the efficacy and safety of JARDIANCE monotherapy.

Treatment-naïve patients with inadequately controlled type 2 diabetes entered an open-label placebo run-in for 2 weeks. At the end of the run-in period, patients who remained inadequately controlled and had an HbA1c between 7 and 10% were randomized to placebo, JARDIANCE 10 mg, JARDIANCE 25 mg, or a reference comparator.

At Week 24, treatment with JARDIANCE 10 mg or 25 mg daily provided statistically significant reductions in HbA1c (p-value <0.0001), fasting plasma glucose (FPG), and body weight compared with placebo (see Table 4 and Figure 3).
### Table 4  Results at Week 24 From a Placebo-Controlled Monotherapy Study of JARDIANCE

<table>
<thead>
<tr>
<th></th>
<th>JARDIANCE 10 mg N=224</th>
<th>JARDIANCE 25 mg N=224</th>
<th>Placebo N=228</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HbA1c (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>7.9</td>
<td>7.9</td>
<td>7.9</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-0.7</td>
<td>-0.8</td>
<td>0.1</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean) (97.5% CI)</td>
<td>-0.7(^b) (-0.9, -0.6)</td>
<td>-0.9(^b) (-1.0, -0.7)</td>
<td>--</td>
</tr>
<tr>
<td>Patients [n (%)] achieving HbA1c &lt;7%</td>
<td>72 (35%)</td>
<td>88 (44%)</td>
<td>25 (12%)</td>
</tr>
<tr>
<td><strong>FPG (mg/dL)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>153</td>
<td>153</td>
<td>155</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-19</td>
<td>-25</td>
<td>12</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean) (95% CI)</td>
<td>-31 (-37, -26)</td>
<td>-36 (-42, -31)</td>
<td>--</td>
</tr>
<tr>
<td><strong>Body Weight</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean) in kg</td>
<td>78</td>
<td>78</td>
<td>78</td>
</tr>
<tr>
<td>% change from baseline (adjusted mean)</td>
<td>-2.8</td>
<td>-3.2</td>
<td>-0.4</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean) (95% CI)</td>
<td>-2.8(^b) (-3.1, -1.9)</td>
<td>-2.8(^b) (-3.4, -2.2)</td>
<td>--</td>
</tr>
</tbody>
</table>

\(^a\)Modified intent to treat population. Last observation on study (LOCF) was used to impute missing data at Week 24. At Week 24, 9.4%, 9.4%, and 30.7% was imputed for patients randomized to JARDIANCE 10 mg, JARDIANCE 25 mg, and placebo, respectively.  
\(^b\)ANCOVA derived p-value <0.0001 (HbA1c: ANCOVA model includes baseline HbA1c, treatment, renal function, and region. Body weight and FPG: same model used as for HbA1c but additionally including baseline body weight/baseline FPG, respectively.)  
\(^c\)FPG (mg/dL); for JARDIANCE 10 mg, n=223, for JARDIANCE 25 mg, n=223, and for placebo, n=226

### Figure 3  Adjusted Mean HbA1c Change at Each Time Point (Completers) and at Week 24 (mITT Population) - LOCF

![Graph showing adjusted mean HbA1c change from baseline at each time point and at Week 24](image)

*Mean change from baseline adjusted for baseline HbA1c, geographical region, and eGFR at baseline.*
At Week 24, the systolic blood pressure was statistically significantly reduced compared to placebo by -2.6 mmHg (placebo-adjusted, p-value=0.0231) in patients randomized to 10 mg of JARDIANCE and by -3.4 mmHg (placebo-corrected, p-value=0.0028) in patients randomized to 25 mg of JARDIANCE.

14.2 Combination Therapy
Add-On Combination Therapy with Metformin
A total of 637 patients with type 2 diabetes participated in a double-blind, placebo-controlled study to evaluate the efficacy and safety of JARDIANCE in combination with metformin.

Patients with type 2 diabetes inadequately controlled on at least 1500 mg of metformin per day entered an open-label 2 week placebo run-in. At the end of the run-in period, patients who remained inadequately controlled and had an HbA1c between 7 and 10% were randomized to placebo, JARDIANCE 10 mg, or JARDIANCE 25 mg.

At Week 24, treatment with JARDIANCE 10 mg or 25 mg daily provided statistically significant reductions in HbA1c (p-value <0.0001), FPG, and body weight compared with placebo (see Table 5).

Table 5 Results at Week 24 From a Placebo-Controlled Study for JARDIANCE used in Combination with Metformin

<table>
<thead>
<tr>
<th></th>
<th>JARDIANCE 10 mg + Metformin N=217</th>
<th>JARDIANCE 25 mg + Metformin N=213</th>
<th>Placebo + Metformin N=207</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c (%)a</td>
<td>7.9</td>
<td>7.9</td>
<td>7.9</td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-0.7</td>
<td>-0.8</td>
<td>-0.1</td>
</tr>
<tr>
<td>Difference from placebo + metformin (adjusted mean) (95% CI)</td>
<td>-0.6b (-0.7, -0.4)</td>
<td>-0.6b (-0.8, -0.5)</td>
<td>--</td>
</tr>
<tr>
<td>Patients [n (%)] achieving HbA1c &lt;7%</td>
<td>75 (38%)</td>
<td>74 (39%)</td>
<td>23 (13%)</td>
</tr>
<tr>
<td>FPG (mg/dL)b</td>
<td>155</td>
<td>149</td>
<td>156</td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-20</td>
<td>-22</td>
<td>6</td>
</tr>
<tr>
<td>Difference from placebo + metformin (adjusted mean)</td>
<td>-26</td>
<td>-29</td>
<td>--</td>
</tr>
<tr>
<td>Body Weight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline mean in kg</td>
<td>82</td>
<td>82</td>
<td>80</td>
</tr>
<tr>
<td>% change from baseline (adjusted mean)</td>
<td>-2.5</td>
<td>-2.9</td>
<td>-0.5</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean) (95%CI)</td>
<td>-2.0c (-2.6, -1.4)</td>
<td>-2.5c (-3.1, -1.9)</td>
<td>--</td>
</tr>
</tbody>
</table>

aModified intent to treat population. Last observation on study (LOCF) was used to impute missing data at Week 24. At Week 24, 9.7%, 14.1%, and 24.6% was imputed for patients randomized to JARDIANCE 10 mg, JARDIANCE 25 mg, and placebo, respectively.
bANCOVA p-value <0.0001 (HbA1c: ANCOVA model includes baseline HbA1c, treatment, renal function, and region. Body weight and FPG: same model used as for HbA1c but additionally including baseline body weight/baseline FPG, respectively.)
cFPG (mg/dL); for JARDIANCE 10 mg, n=216, for JARDIANCE 25 mg, n=213, and for placebo, n=207

At Week 24, the systolic blood pressure was statistically significantly reduced compared to placebo by -4.1 mmHg (placebo-corrected, p-value <0.0001) for JARDIANCE 10 mg and -4.8 mmHg (placebo-corrected, p-value <0.0001) for JARDIANCE 25 mg.

Add-On Combination Therapy with Metformin and Sulfonylurea
A total of 666 patients with type 2 diabetes participated in a double-blind, placebo-controlled study to evaluate the efficacy and safety of JARDIANCE in combination with metformin plus a sulfonylurea.

Reference ID: 3603272
Patients with inadequately controlled type 2 diabetes on at least 1500 mg per day of metformin and on a sulfonylurea, entered a 2 week open-label placebo run-in. At the end of the run-in, patients who remained inadequately controlled and had an HbA1c between 7% and 10% were randomized to placebo, JARDIANCE 10 mg, or JARDIANCE 25 mg.

Treatment with JARDIANCE 10 mg or 25 mg daily provided statistically significant reductions in HbA1c (p-value <0.0001), FPG, and body weight compared with placebo (see Table 6).

Table 6   Results at Week 24 from a Placebo-Controlled Study for JARDIANCE in Combination with Metformin and Sulfonylurea

<table>
<thead>
<tr>
<th></th>
<th>JARDIANCE 10 mg + Metformin</th>
<th>JARDIANCE 25 mg + Metformin</th>
<th>Placebo + Metformin + SU</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+ SU N=225</td>
<td>+ SU N=216</td>
<td>N=225</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>8.1</td>
<td>8.1</td>
<td>8.2</td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>-0.8</td>
<td>-0.8</td>
<td>-0.2</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-0.6b (-0.8, -0.5)</td>
<td>-0.6b (-0.7, -0.4)</td>
<td>--</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean) (95% CI)</td>
<td>55 (26%)</td>
<td>65 (32%)</td>
<td>20 (9%)</td>
</tr>
<tr>
<td>Patients [n (%)] achieving HbA1c &lt;7%</td>
<td>55 (26%)</td>
<td>65 (32%)</td>
<td>20 (9%)</td>
</tr>
<tr>
<td>FPG (mg/dL)</td>
<td>151</td>
<td>156</td>
<td>152</td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>-23</td>
<td>-23</td>
<td>6</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-29</td>
<td>-29</td>
<td>--</td>
</tr>
<tr>
<td>Body Weight</td>
<td>77</td>
<td>78</td>
<td>76</td>
</tr>
<tr>
<td>% change from baseline (adjusted mean)</td>
<td>-2.9</td>
<td>-3.2</td>
<td>-0.5</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean) (95% CI)</td>
<td>-2.4b (-3.0, -1.8)</td>
<td>-2.7b (-3.3, -2.1)</td>
<td>--</td>
</tr>
</tbody>
</table>

aModified intent to treat population. Last observation on study (LOCF) was used to impute missing data at Week 24. At Week 24, 17.8%, 16.7%, and 25.3% was imputed for patients randomized to JARDIANCE 10 mg, JARDIANCE 25 mg, and placebo, respectively.
bANCOVA p-value <0.0001 (HbA1c: ANCOVA model includes baseline HbA1c, treatment, renal function, and region. Body weight and FPG: same model used as for HbA1c but additionally including baseline body weight/baseline FPG, respectively.)
cFPG (mg/dL); for JARDIANCE 10 mg, n=225, for JARDIANCE 25 mg, n=215, for placebo, n=224

Active-Controlled Study versus Glimepiride in Combination with Metformin
The efficacy of JARDIANCE was evaluated in a double-blind, glimepiride-controlled, study in 1545 patients with type 2 diabetes with insufficient glycemic control despite metformin therapy.

Patients with inadequate glycemic control and an HbA1c between 7% and 10% after a 2-week run-in period were randomized to glimepiride or JARDIANCE 25 mg.

At Week 52, JARDIANCE 25 mg and glimepiride lowered HbA1c and FPG (see Table 7, Figure 4). The difference in observed effect size between JARDIANCE 25 mg and glimepiride excluded the pre-specified non-inferiority margin of 0.3%. The mean daily dose of glimepiride was 2.7 mg and the maximal approved dose in the United States is 8 mg per day.
Table 7  Results at Week 52 from an Active-Controlled Study Comparing JARDIANCE to Glimepiride as Add-On Therapy in Patients Inadequately Controlled on Metformin

<table>
<thead>
<tr>
<th></th>
<th>JARDIANCE 25 mg + Metformin N=765</th>
<th>Glimepiride + Metformin N=780</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HbA1c (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>7.9</td>
<td>7.9</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-0.7</td>
<td>-0.7</td>
</tr>
<tr>
<td>Difference from glimepiride (adjusted mean) (97.5% CI)</td>
<td>-0.07b (-0.15, 0.01)</td>
<td>--</td>
</tr>
<tr>
<td><strong>FPG (mg/dL)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>150</td>
<td>150</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-19</td>
<td>-9</td>
</tr>
<tr>
<td><strong>Body Weight</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline mean in kg</td>
<td>82.5</td>
<td>83</td>
</tr>
<tr>
<td>% change from baseline (adjusted mean)</td>
<td>-3.9</td>
<td>2.0</td>
</tr>
<tr>
<td>Difference from comparator (adjusted mean) (95% CI)</td>
<td>-5.9c (-6.3, -5.5)</td>
<td>--</td>
</tr>
</tbody>
</table>

*aModified intent to treat population. Last observation on study (LOCF) was used to impute data missing at Week 52. At Week 52 data was imputed for 15.3% and 21.9% of patients randomized to JARDIANCE 25 mg and glimepiride, respectively.

bNon-inferior, ANCOVA model p-value <0.0001 (HbA1c: ANCOVA model includes baseline HbA1c, treatment, renal function, and region).

cANCOVA p-value <0.0001 (Body weight and FPG: same model used as for HbA1c but additionally including baseline body weight/baseline FPG, respectively.)

dFPG (mg/dL); for JARDIANCE 25 mg, n=764, for placebo, n=779

Figure 4  Adjusted mean HbA1c Change at Each Time Point (Completers) and at Week 52 (mITT Population) - LOCF

*Mean change from baseline adjusted for baseline HbA1c, geographical region, and eGFR at baseline.

Reference ID: 3603272
At Week 52, the adjusted mean change from baseline in systolic blood pressure was -3.6 mmHg, compared to 2.2 mmHg for glimepiride. The differences between treatment groups for systolic blood pressure was statistically significant (p-value <0.0001).

**Add-On Combination Therapy with Pioglitazone with or without Metformin**

A total of 498 patients with type 2 diabetes participated in a double-blind, placebo-controlled study to evaluate the efficacy and safety of JARDIANCE in combination with pioglitazone, with or without metformin.

Patients with inadequately controlled type 2 diabetes on metformin at a dose of at least 1500 mg per day and pioglitazone at a dose of at least 30 mg per day were placed into an open-label placebo run-in for 2 weeks. Patients with inadequate glycemic control and an HbA1c between 7% and 10% after the run-in period were randomized to placebo, JARDIANCE 10 mg, or JARDIANCE 25 mg.

Treatment with JARDIANCE 10 mg or 25 mg daily resulted in statistically significant reductions in HbA1c (p-value <0.0001), FPG, and body weight compared with placebo (see Table 8).

**Table 8  Results of Placebo-Controlled Study for JARDIANCE in Combination Therapy with Pioglitazone**

<table>
<thead>
<tr>
<th></th>
<th>JARDIANCE 10 mg + Pioglitazone N=165</th>
<th>JARDIANCE 25 mg + Pioglitazone N=168</th>
<th>Placebo + Pioglitazone N=165</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HbA1c (%)</strong>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>8.1</td>
<td>8.1</td>
<td>8.2</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-0.6</td>
<td>-0.7</td>
<td>-0.1</td>
</tr>
<tr>
<td>Difference from placebo + pioglitazone (adjusted mean) (95% CI)</td>
<td>-0.5b (-0.7, -0.3)</td>
<td>-0.6b (-0.8, -0.4)</td>
<td>--</td>
</tr>
<tr>
<td>Patients [n (%)] achieving HbA1c &lt;7%</td>
<td>36 (24%)</td>
<td>48 (30%)</td>
<td>12 (8%)</td>
</tr>
<tr>
<td><strong>FPG (mg/dL)c</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>152</td>
<td>152</td>
<td>152</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-17</td>
<td>-22</td>
<td>7</td>
</tr>
<tr>
<td>Difference from placebo + pioglitazone (adjusted mean) (97.5% CI)</td>
<td>-23b (-31.8, -15.2)</td>
<td>-28b (-36.7, -20.2)</td>
<td>--</td>
</tr>
<tr>
<td><strong>Body Weight</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline mean in kg</td>
<td>78</td>
<td>79</td>
<td>78</td>
</tr>
<tr>
<td>% change from baseline (adjusted mean)</td>
<td>-2.0</td>
<td>-1.8</td>
<td>-0.6</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean) (95% CI)</td>
<td>-2.6b (-3.4, -1.8)</td>
<td>-2.4b (-3.2, -1.6)</td>
<td>--</td>
</tr>
</tbody>
</table>

*Modified intent to treat population. Last observation on study (LOCF) was used to impute missing data at Week 24. At Week 24, 10.9%, 8.3% and 20.6% was imputed for patients randomized to JARDIANCE 10 mg, JARDIANCE 25 mg, and placebo respectively. bANCOVA p-value <0.0001 (HbA1c: ANCOVA model includes baseline HbA1c, treatment, renal function, and background medication. Body weight and FPG: same model used as for HbA1c but additionally including baseline body weight/baseline FPG, respectively.)

cFPG (mg/dL); for JARDIANCE 10 mg, n=163

**Add-On Combination with Insulin with or without Metformin and/or Sulfonylureas**

A total of 494 patients with type 2 diabetes inadequately controlled on insulin, or insulin in combination with oral drugs participated in a double-blind, placebo-controlled study to evaluate the efficacy of JARDIANCE as add-on therapy to insulin over 78 weeks.

Patients entered a 2-week placebo run-in period on basal insulin (e.g., insulin glargine, insulin detemir, or NPH insulin) with or without metformin and/or sulfonylurea background therapy. Following the run-in period, patients with inadequate glycemic control were randomized to the addition of JARDIANCE 10 mg, JARDIANCE 25 mg, or placebo. Patients were maintained on a stable dose of insulin prior to enrollment,
during the run-in period, and during the first 18 weeks of treatment. For the remaining 60 weeks, insulin could be adjusted. The mean total daily insulin dose at baseline for JARDIANCE 10 mg, 25 mg, and placebo was 45 IU, 48 IU, and 48 IU, respectively.

JARDIANCE used in combination with insulin (with or without metformin and/or sulfonylurea) provided statistically significant reductions in HbA1c and FPG compared to placebo after both 18 and 78 weeks of treatment (see Table 9). JARDIANCE 10 mg or 25 mg daily also resulted in statistically significantly greater percent body weight reduction compared to placebo.

**Table 9** Results at Week 18 and 78 for a Placebo-Controlled Study for JARDIANCE in Combination with Insulin

<table>
<thead>
<tr>
<th></th>
<th>18 weeks (no insulin adjustment)</th>
<th>78 weeks (adjustable insulin dose after 18 weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>JARDIANCE 10 mg + Insulin N=169</td>
<td>JARDIANCE 25 mg + Insulin N=155</td>
</tr>
<tr>
<td>HbA1c (%)a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>8.3</td>
<td>8.3</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-0.6</td>
<td>-0.7</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean) (97.5% CI)</td>
<td>-0.6b (-0.8, -0.4)</td>
<td>-0.7b (-0.9, -0.5)</td>
</tr>
<tr>
<td>Patients (%) achieving HbA1c &lt;7%</td>
<td>18.0</td>
<td>19.5</td>
</tr>
<tr>
<td>FPG (mg/dL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>138</td>
<td>146</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean, SE)</td>
<td>-17.9 (3.2)</td>
<td>-19.1 (3.3)</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean) (95% CI)</td>
<td>-28.2b (-37.0, -19.5)</td>
<td>-29.5b (-38.4, -20.6)</td>
</tr>
<tr>
<td>Body Weight</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline mean in kg</td>
<td>92</td>
<td>95</td>
</tr>
<tr>
<td>% change from baseline (adjusted mean)</td>
<td>-1.8</td>
<td>-1.4</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean) (95% CI)</td>
<td>-1.7d (-3.0, -0.5)</td>
<td>-1.3e (-2.5, -0.0)</td>
</tr>
</tbody>
</table>

aModified intent to treat population. Last observation on study (LOCF) was used to impute missing data at Week 18 and 78. At Week 18, 21.3%, 30.3%, and 21.8% was imputed for patients randomized to JARDIANCE 10 mg, JARDIANCE 25 mg, and placebo respectively. At Week 78, 32.5%, 38.1% and 42.4% was imputed for patients randomized to JARDIANCE 10 mg, JARDIANCE 25 mg, and placebo respectively.

bANCOVA p-value <0.0001 (HbA1c: ANCOVA model includes baseline HbA1c, treatment, and region; FPG: MMRM model includes baseline FPG, baseline HbA1c, treatment, region, visit and visit by treatment interaction. Body weight: MMRM model includes baseline body weight, baseline HbA1c, treatment, region, visit and visit by treatment interaction.

cp-value=0.0049
dp-value=0.0052
ep=0.0463

Reference ID: 3603272
14.3 Renal Impairment

A total of 738 patients with type 2 diabetes and a baseline eGFR less than 90 mL/min/1.73 m² participated in a randomized, double-blind, placebo-controlled, parallel-group to evaluate the efficacy and safety of JARDIANCE in patients with type 2 diabetes and renal impairment. The trial population comprised of 290 patients with mild renal impairment (eGFR 60 to less than 90 mL/min/1.73 m²), 374 patients with moderate renal impairment (eGFR 30 to less than 60 mL/min/1.73 m²), and 74 with severe renal impairment (eGFR less than 30 mL/min/1.73 m²). A total of 194 patients with moderate renal impairment had a baseline eGFR of 30 to less than 45 mL/min/1.73 m² and 180 patients a baseline eGFR of 45 to less than 60 mL/min/1.73 m².

At Week 24, JARDIANCE 25 mg provided statistically significant reduction in HbA1c relative to placebo in patients with mild to moderate renal impairment (see Table 10). A statistically significant reduction relative to placebo was also observed with JARDIANCE 25 mg in patients with either mild [-0.7 (95% CI: -0.9, -0.5)] or moderate [-0.4 (95% CI: -0.6, -0.3)] renal impairment and with JARDIANCE 10 mg in patients with mild [-0.5 (95% CI: -0.7, -0.3)] renal impairment.

The glucose lowering efficacy of JARDIANCE 25 mg decreased with decreasing level of renal function in the mild to moderate range. Least square mean Hb1Ac changes at 24 weeks were -0.6%, -0.5%, and -0.2% for those with a baseline eGFR of 60 to less than 90 mL/min/1.73 m², 45 to less than 60 mL/min/1.73 m², and 30 to less than 45 mL/min/1.73 m², respectively [see Dosage and Administration (2) and Use in Specific Populations (8.6)]. For placebo, least square mean HbA1c changes at 24 weeks were 0.1%, -0.1%, and 0.2% for patients with a baseline eGFR of 60 to less than 90 mL/min/1.73 m², 45 to less than 60 mL/min/1.73 m², and 30 to less than 45 mL/min/1.73 m², respectively.

### Table 10  Results at Week 24 (LOCF) of Placebo-Controlled Study for JARDIANCE in Patients with Type 2 Diabetes and Renal Impairment

<table>
<thead>
<tr>
<th></th>
<th>Mild and Moderate Impairmentb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>JARDIANCE 25 mg</td>
</tr>
<tr>
<td>HbA1c</td>
<td></td>
</tr>
<tr>
<td>Number of patients</td>
<td>n=284</td>
</tr>
<tr>
<td>Comparison vs placebo (adjusted mean) (95% CI)</td>
<td>-0.5 (95% CI: -0.6, -0.4)</td>
</tr>
</tbody>
</table>

*p-value <0.0001 (HbA1c: ANCOVA model includes baseline HbA1c, treatment, renal function, and background medication)

b eGFR 30 to less than 90 mL/min/1.73 m². Modified intent to treat population. Last observation on study (LOCF) was used to impute missing data at Week 24. At Week 24, 24.6% and 26.2% was imputed for patients randomized to JARDIANCE 25 mg and placebo, respectively.

For patients with severe renal impairment, the analyses of changes in HbA1c and FPG showed no discernible treatment effect of JARDIANCE 25 mg compared to placebo [see Dosage and Administration (2.2) and Use in Specific Populations (8.6)].

16 HOW SUPPLIED/STORAGE AND HANDLING

JARDIANCE tablets are available in 10 mg and 25 mg strengths as follows:

### 10 mg tablets:
- pale yellow, round, biconvex and bevel-edged, film-coated tablets debossed with “S 10” on one side and the Boehringer Ingelheim company symbol on the other side.
- Bottles of 30 (NDC 0597-0152-30)
- Bottles of 90 (NDC 0597-0152-90)
- Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0152-37), institutional pack.

### 25 mg tablets:
- pale yellow, round, biconvex and bevel-edged, film-coated tablets debossed with “S 25” on one side and the Boehringer Ingelheim company symbol on the other side.
- Bottles of 30 (NDC 0597-0153-30)
- Bottles of 90 (NDC 0597-0153-90)
- Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0153-37), institutional pack.
**25 mg tablets:** pale yellow, oval, biconvex film-coated tablets, debossed with “S 25” on one side and the Boehringer Ingelheim company symbol on the other side.

Bottles of 30 (NDC 0597-0153-30)
Bottles of 90 (NDC 0597-0153-90)
Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0153-37), institutional pack.

Dispense in a well-closed container as defined in the USP.

**Storage**
*Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F)* [see USP Controlled Room Temperature].

**17 PATIENT COUNSELING INFORMATION**

Advise the patient to read the FDA-approved patient labeling (Patient Information).

**Instructions**

Instruct patients to read the Patient Information before starting JARDIANCE therapy and to reread it each time the prescription is renewed. Instruct patients to inform their doctor or pharmacist if they develop any unusual symptom, or if any known symptom persists or worsens.

Inform patients of the potential risks and benefits of JARDIANCE and of alternative modes of therapy. Also inform patients about the importance of adherence to dietary instructions, regular physical activity, periodic blood glucose monitoring and HbA1c testing, recognition and management of hypoglycemia and hyperglycemia, and assessment for diabetes complications. Advise patients to seek medical advice promptly during periods of stress such as fever, trauma, infection, or surgery, as medication requirements may change.

Instruct patients to take JARDIANCE only as prescribed. If a dose is missed, it should be taken as soon as the patient remembers. Advise patients not to double their next dose.

Inform patients that the most common adverse reactions associated with the use of JARDIANCE are urinary tract infections and mycotic genital infections.

Inform female patients of child bearing age that the use of JARDIANCE during pregnancy has not been studied in humans, and that JARDIANCE should only be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Based on animal data, JARDIANCE may cause fetal harm in the second and third trimesters. Instruct patients to report pregnancies to their physicians as soon as possible.

Inform nursing mothers to discontinue JARDIANCE or nursing, taking into account the important of the drug to the mother. It is not known if JARDIANCE is excreted in breast milk; however, based on animal data, JARDIANCE may cause harm to nursing infants.

**Hypotension**

Inform patients that hypotension may occur with JARDIANCE and advise them to contact their healthcare provider if they experience such symptoms [*see Warnings and Precautions (5.1)*]. Inform patients that dehydration may increase the risk for hypotension, and to have adequate fluid intake.

**Urinary Tract Infections**

Inform patients of the potential for urinary tract infections. Provide them with information on the symptoms of urinary tract infections. Advise them to seek medical advice if such symptoms occur.
Genital Mycotic Infections in Females (e.g., Vulvovaginitis)
Inform female patients that vaginal yeast infections may occur and provide them with information on the signs and symptoms of vaginal yeast infections. Advise them of treatment options and when to seek medical advice [see Warnings and Precautions (5.4)].

Genital Mycotic Infections in Males (e.g., Balanitis or Balanoposthitis)
Inform male patients that yeast infection of penis (e.g., balanitis or balanoposthitis) may occur, especially in uncircumcised males and patients with chronic and recurrent infections. Provide them with information on the signs and symptoms of balanitis and balanoposthitis (rash or redness of the glans or foreskin of the penis). Advise them of treatment options and when to seek medical advice [see Warnings and Precautions (5.4)].

Laboratory Tests
Inform patients that renal function should be assessed prior to initiation of JARDIANCE and monitored periodically thereafter.

Inform patients that elevated glucose in urinalysis is expected when taking JARDIANCE.

Inform patients that response to all diabetic therapies should be monitored by periodic measurements of blood glucose and HbA1c levels, with a goal of decreasing these levels toward the normal range. Hemoglobin A1c monitoring is especially useful for evaluating long-term glycemic control.
IT6062A
304561-01

IT6063A
304562-01
PATIENT INFORMATION

JARDIANCE® (jar DEE ans)
(empagliflozin)
Tablets

Read this Patient Information before you start taking JARDIANCE and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or treatment.

What is the most important information I should know about JARDIANCE?

JARDIANCE can cause serious side effects, including:

- **Dehydration.** JARDIANCE can cause some people to have dehydration (the loss of body water and salt). Dehydration may cause you to feel dizzy, faint, light-headed, or weak, especially when you stand up (orthostatic hypotension).

  You may be at higher risk of dehydration if you:
  - have low blood pressure
  - take medicines to lower your blood pressure, including diuretics (water pill)
  - are on low sodium (salt) diet
  - have kidney problems
  - are 65 years of age or older

- **Vaginal yeast infection.** Women who take JARDIANCE may get vaginal yeast infections. Symptoms of a vaginal yeast infection include:
  - vaginal odor
  - white or yellowish vaginal discharge (discharge may be lumpy or look like cottage cheese)
  - vaginal itching

- **Yeast infection of the penis (balanitis or balanoposthitis).** Men who take JARDIANCE may get a yeast infection of the skin around the penis. Certain men who are not circumcised may have swelling of the penis that makes it difficult to pull back the skin around the tip of the penis. Other symptoms of yeast infection of the penis include:
  - redness, itching, or swelling of the penis
  - rash of the penis
  - foul smelling discharge from the penis
  - pain in the skin around penis

Talk to your doctor about what to do if you get symptoms of a yeast infection of the vagina or penis. Your doctor may suggest you use an over-the-counter antifungal medicine. Talk to your doctor right away if you use an over-the-counter antifungal medication and your symptoms do not go away.

What is JARDIANCE?

- JARDIANCE is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
- JARDIANCE is not for people with type 1 diabetes.
- JARDIANCE is not for people with diabetic ketoacidosis (increased ketones in the blood or urine).
• It is not known if JARDIANCE is safe and effective in children under 18 years of age.

Who should not take JARDIANCE?

Do not take JARDIANCE if you:
• are allergic to empagliflozin or any of the ingredients in JARDIANCE. See the end of this leaflet for a list of ingredients in JARDIANCE.
• have severe kidney problems or are on dialysis

What should I tell my doctor before using JARDIANCE?

Before you take JARDIANCE, tell your doctor if you:
• have kidney problems
• have liver problems
• have a history of urinary tract infections or problems with urination
• have any other medical conditions
• are pregnant or planning to become pregnant. It is not known if JARDIANCE will harm your unborn baby. If you are pregnant, talk with your doctor about the best way to control your blood sugar while you are pregnant.
• are breastfeeding or plan to breastfeed. It is not known if JARDIANCE passes into your breast milk. Talk with your doctor about the best way to feed your baby if you take JARDIANCE.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

JARDIANCE may affect the way other medicines work, and other medicines may affect how JARDIANCE works.

Especially tell your doctor if you take:
• diuretics (water pills)
• insulin or other medicines that can lower your blood sugar

Ask your doctor or pharmacist for a list of these medicines if you are not sure if your medicine is listed above.

How should I take JARDIANCE?

• Take JARDIANCE exactly as your doctor tells you to take it.
• Take JARDIANCE by mouth 1 time in the morning each day, with or without food.
• Your doctor may change your dose if needed.
• If you miss a dose, take it as soon as you remember. If you do not remember until it is time for your next dose, skip the missed dose and go back to your regular schedule. Do not take two doses of JARDIANCE at the same time. Talk with your doctor if you have questions about a missed dose.
• Your doctor may tell you to take JARDIANCE along with other diabetes medicines. Low blood sugar can happen more often when JARDIANCE is taken with certain other diabetes medicines. See “What are the possible side effects of JARDIANCE?”
• If you take too much JARDIANCE, call your doctor or go to the nearest hospital emergency room right away.
• When your body is under some types of stress, such as fever, trauma (such as a car accident), infection, or surgery, the amount of diabetes medicine that you need may change. Tell your doctor right away if you have any of these conditions and follow your doctor’s instructions.
• Check your blood sugar as your doctor tells you to.
• Stay on your prescribed diet and exercise program while taking JARDIANCE.
• Talk to your doctor about how to prevent, recognize and manage low blood sugar (hypoglycemia), high blood sugar (hyperglycemia), and complications of diabetes.
• Your doctor will check your diabetes with regular blood tests, including your blood sugar levels and your hemoglobin HbA1c.
• When taking JARDIANCE, you may have sugar in your urine, which will show up on a urine test.

What are the possible side effects of JARDIANCE?

JARDIANCE may cause serious side effects, including:
• See “What is the most important information I should know about JARDIANCE.”
• low blood sugar (hypoglycemia). If you take JARDIANCE with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take JARDIANCE. Signs and symptoms of low blood sugar may include:
  o headache
  o drowsiness
  o weakness
  o dizziness
  o confusion
  o irritability
  o hunger
  o fast heart beat
  o sweating
  o shaking or feeling jittery
• kidney problems, especially in people 75 years of age or older and people who already have kidney problems
• increased fats in your blood (cholesterol)

The most common side effects of JARDIANCE include:
• urinary tract infection. Signs and symptoms of a urinary tract infection may include burning feeling when passing urine, urine that looks cloudy, pain in the pelvis, or back pain.

These are not all the possible side effects of JARDIANCE. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store JARDIANCE?
Store JARDIANCE at room temperature between 68°F to 77°F (20°C to 25°C).

General information about the safe and effective use of JARDIANCE.

This Patient Information summarizes the most important information about JARDIANCE. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about JARDIANCE that is written for health professionals.

For more information about JARDIANCE, go to www.jardiance.com, scan the code below, or call Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257 or (TTY) 1-800-459-9906.
What are the ingredients in JARDIANCE?

Active Ingredient: empagliflozin

Inactive Ingredients: lactose monohydrate, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate. In addition, the film coating contains the following inactive ingredients: hypromellose, titanium dioxide, talc, polyethylene glycol, and yellow ferric oxide.

Distributed by:
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, CT 06877 USA

Marketed by:
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, CT 06877 USA
and
Eli Lilly and Company
Indianapolis, IN 46285 USA

Licensed from:
Boehringer Ingelheim International GmbH
Ingelheim, Germany

Boehringer Ingelheim Pharmaceuticals, Inc. either owns or uses the Jardiance® trademark under license.

The other trademarks referenced are owned by third parties not affiliated with Boehringer Ingelheim Pharmaceuticals, Inc.

Copyright © 2014 Boehringer Ingelheim International GmbH
ALL RIGHTS RESERVED

IT5728AG312014
304584-01

IT6061A
304563-01

IT6062A
304561-01

IT6063A
304562-01

Issued August 2014
Jardiance®
(empagliflozin)
Tablets
25 mg

This unit dose package is not child-resistant. If dispensed for unpatient use, a child-resistant container should be utilized.

Rx only

30 tablets
3 blister cards. Each card contains 10 tablets.

Boehringer
Ingelheim

Please visit our website at www.jardiance.com or scan the code, or call 1-800-942-6273 or (TTY) 1-800-338-9906

Reference ID: 3603272
<table>
<thead>
<tr>
<th>Jardiance®</th>
<th>Jardiance®</th>
<th>Jardiance®</th>
<th>Jardiance®</th>
<th>Jardiance®</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 mg per tablet</td>
<td>10 mg per tablet</td>
<td>10 mg per tablet</td>
<td>10 mg per tablet</td>
<td>10 mg per tablet</td>
</tr>
<tr>
<td>No Tablet</td>
<td>No Tablet</td>
<td>No Tablet</td>
<td>No Tablet</td>
<td>No Tablet</td>
</tr>
<tr>
<td>Here</td>
<td>Here</td>
<td>Here</td>
<td>Here</td>
<td>Here</td>
</tr>
</tbody>
</table>

**Note:** The image contains a table with medication information. Each row represents a different dosage form of Jardiance®.